{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-004296","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2022-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.239742+00:00","generated_at":"2026-06-25T02:59:51.065928+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Anika shareholders approve 250,000-share increase in 2017 incentive plan, reelect directors","bullets":["Stockholders approved amendment increasing shares under 2017 Omnibus Plan from 4.6M to 4.85M; 10.1M in favor, 2.25M against.","Cheryl R. Blanchard (Ph.D.) reelected as Class II director with 11.36M votes for, 1.11M against; Glenn R. Larsen (Ph.D.) with 11.98M for, 0.32M against.","Ratification of Deloitte & Touche as auditor passed with 13.13M for, 0.08M against, 15.3K abstain; advisory say-on-pay passed with 12.15M for.","Meeting turnout: 13.22M shares present (91.07% of voting power)."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-004296","json":"https://secwatch.observer/filing/0001171843-22-004296.json","markdown":"https://secwatch.observer/filing/0001171843-22-004296.md","text":"https://secwatch.observer/filing/0001171843-22-004296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184322004296/0001171843-22-004296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184322004296/f8k_060822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:59:51.065928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}